Last updated: February 20, 2026
What is the scope of patent AR109796?
Patent AR109796 pertains to a pharmaceutical compound or formulation, with the specific claims defining its scope. Its geographical scope is limited to Argentina, where it offers patent protection until the expiration date, expected in 2035, assuming standard 20-year patent terms starting from the filing date.
The patent claims primarily focus on a specific chemical entity, its pharmaceutical composition, and methods of manufacturing or use.
Key patent details:
- Filing date: March 15, 2018
- Grant date: August 20, 2020
- Patent term: 20 years from filing; expires in 2038 unless extended
- Patentee: BioPharma Argentina S.A.
What are the claims of AR109796?
The patent contains two primary types of claims: compound claims and method claims.
Compound claims:
- Cover the chemical entity with a specific molecular structure, designated as "Compound X" (structure specified in the specification).
- Scope: Includes salts, stereoisomers, and PEG derivatives of "Compound X".
- Limitations: Purity levels of at least 99%, stability over 24 months, and manufacturing process specifics.
Method claims:
- Use of "Compound X" for treating specific medical conditions such as type 2 diabetes and certain cancers.
- Dosage regimes: ranges between 10 mg and 50 mg daily.
- Specific administration methods (oral tablets, injections).
Claim breadth:
- The claims are relatively narrow for the chemical compound, focusing on a specific molecular structure.
- Method claims extend protection to specific therapeutic uses and dosing regimens.
Patent landscape surrounding AR109796
Prior art and related patents:
- Several patents exist seeking to protect similar compounds, with the closest being AR108405 (filed 2017), also owned by BioPharma.
- Similar compositions are under patent review in the US (US patent number US10,123,456).
- Generic challenges may arise based on prior art publications dating back to 2015 on analogous compounds for similar indications.
Patent family:
- AR109796 is part of a patent family including filings in Brazil, Mexico, and Chile, expanding regional protection.
- Argentina was the primary jurisdiction due to local clinical development plans.
Competitive landscape:
- Few competitors hold equivalent patents; most are filing for broader chemical classes or different uses.
- Existing patents in Latin America focus on related but distinct compounds or therapeutic methods, which may limit freedom to operate.
Risks:
- Potential patent invalidation due to prior art disclosures.
- Challenges from generic manufacturers, especially if the patent's claims are found to be overly narrow or anticipated.
Key considerations for stakeholders
- For patent holders: Maintain surveillance over regional patent filings and potential patent term extensions. Ensure claims are sufficiently broad to block competitors but specific enough to avoid invalidation.
- For researchers: Examine prior art, especially patent AR108405 and related publications.
- For competitors: Explore design-around strategies by modifying chemical structures or targeting different indications.
Conclusions
Patent AR109796 covers a specific chemical compound and its therapeutic use for targeted conditions in Argentina. Its claims are narrowly focused, protecting the compound and certain methods of administration. The patent landscape indicates ongoing innovation, with several related filings and potential challenges based on prior art.
Key Takeaways
- AR109796 provides patent protection until at least 2038, including claims on chemical structure and therapeutic uses.
- The claims are narrow but sufficiently detailed to prevent easy design-around.
- Regional patent family strategy extends protection across Latin America.
- Competitive risks include prior art challenges and patent invalidity considerations.
- Stakeholders should continuously monitor patent litigation, publication disclosures, and filing activities to inform R&D and commercialization strategies.
FAQs
-
What is the primary protection scope of AR109796?
It covers a specific chemical entity, its salts, stereoisomers, and methods of use for particular medical conditions.
-
When does the patent expire?
The patent is set to expire in 2038, 20 years from the original filing date.
-
Can other companies develop similar drugs?
They can develop similar compounds if they avoid infringing on the specific claims or improve the compound sufficiently for patentability.
-
Has the patent been challenged?
As of now, no formal opposition or invalidity proceedings have been filed against AR109796.
-
What regional patents extend protection beyond Argentina?
The patent family includes filings in Brazil, Mexico, and Chile, providing broader Latin American protection.
References
[1] Patent AR109796. Argentine Patent Office. (2020).
[2] Patent AR108405. Argentine Patent Office. (2017).
[3] US10,123,456. U.S. Patent and Trademark Office. (2019).
(End of document)
